The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”

News of the hires comes weeks after Schrödinger pulled in more cash to fund its evolution into a biotech with an internal pipeline.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding.

Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.